Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Outsourcing
Lonza to add large-scale dosage-form services
by Rick Mullin
July 14, 2022
| A version of this story appeared in
Volume 100, Issue 25
Lonza plans to spend over $500 million to build a commercial-scale fill-and-finish facility for biologic drugs at a site in Stein, Switzerland. The drug services company launched its dosage-form drug business in Basel, Switzerland, in 2016, for injectable and infusible versions of antibodies, drug conjugates, peptides, and small molecules, mostly at clinical scale. Lonza has since added dosage-form services at its plants in Visp, Switzerland, and Guangzhou, China. It acquired the Stein site from Novartis in 2019.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter